Emicizumab

Category: Blood Clotting (Hemostasis)



Emicizumab Overview

Emicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Chugai (a subsidiary of Roche).[1] A Phase I clinical trial found that it was well tolerated by healthy subjects.[2] In November 2017, it was approved by the US FDA for treatment of haemophilia A patients who had developed resistance to other treatments.[3] It was subsequently approved by the US FDA in April 2018 under the breakth...

Read more Emicizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Emicizumab

Recent Emicizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Emicizumab
  • Injection: 105mg/0.7ml, 150mg, 30mg/ml, 60mg/0.4ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Emicizumab or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 March 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA